Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (symbol: QNRX) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products for rare and orphan diseases. Founded with a commitment to addressing unmet medical needs, Quoin focuses on innovating treatments that can make a significant impact on patients’ lives.
Quoin’s research and development pipeline includes potential treatments for a range of conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa. Their work is particularly focused on Netherton Syndrome, a rare genetic disorder characterized by defective skin barrier function.
Recently, Quoin made significant strides in its clinical studies for Netherton Syndrome. Protocol amendments, based on initial positive data, were approved by the FDA and include increasing study sizes, modifying dosing frequencies, and broadening eligibility criteria. These changes aim to enhance the potential for a successful outcome.
Furthermore, Quoin expanded its intellectual property portfolio by filing both US and international patent applications for a novel combination product to treat Netherton Syndrome. They are also exploring additional patent opportunities related to the clinical and manufacturing aspects of their products.
Financially, Quoin has strengthened its position through a successful public offering and the execution of an equity line of credit arrangement, extending their cash runway into late 2025. This financial stability supports the company as it pursues key milestones in its development pipeline.
Under the leadership of Dr. Michael Myers, Quoin Pharmaceuticals is poised to make significant advancements in the field of rare and orphan disease treatments. The company continues to engage with the investment community and stakeholders through various communication channels, ensuring transparency and building investor confidence.
To stay updated on Quoin Pharmaceuticals' latest developments, visit their website or follow them on LinkedIn.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the dosing of the first patient in its open-label clinical trial for QRX003 targeting Netherton Syndrome. This study evaluates the safety and efficacy of QRX003 in patients receiving off-label systemic therapy over a twelve-week period. Various clinical endpoints will be assessed, including Investigator Global Assessment and Patient Global Assessment. Concurrently, Quoin is also running a double-blind vehicle-controlled study for QRX003. The company expects to report topline data from this trial in the latter half of 2023. These efforts position QRX003 as a potential standard of care for Netherton patients.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the dosing of the first patient in a double-blinded clinical trial for QRX003 targeting Netherton Syndrome. The company initiated a second trial assessing QRX003 in patients on off-label therapy, cleared by the FDA. Quoin partnered with Queensland University of Technology to advance dermatological research, aiming for clinical testing by late 2023. Financially, Quoin reported a net loss of approximately $9.4 million for 2022, with $12.9 million in cash. A recent public offering raised $6 million, extending the cash runway into the second half of 2024, crucial for development efforts.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) will release its 2022 fourth quarter and year-end financial results on March 8, 2023, after market close. A conference call and webcast are scheduled for March 9, 2023, at 8:30 AM ET to discuss these results. Investors can join the call by calling 1-877-270-2148 domestically or 1-412-902-6510 internationally. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline including treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa. For more details, visit their official website.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
What is Quoin Pharmaceuticals?
What diseases is Quoin Pharmaceuticals targeting?
What are the recent achievements of Quoin Pharmaceuticals?
Who is leading Quoin Pharmaceuticals?
How can I stay updated on Quoin Pharmaceuticals' news?
What is Netherton Syndrome?
What financial strategies has Quoin Pharmaceuticals implemented recently?
What is unique about Quoin Pharmaceuticals' approach?
Are Quoin Pharmaceuticals' statements forward-looking?
Where is Quoin Pharmaceuticals listed?
